Xencor Inc (XNCR): Free Cash Flow
-$138.27M
Year ended 2025-12-31
-$208.28M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$138.27M | n/m | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | -$208.28M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | -$96.37M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$14.01M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$30.15M | n/m | 2025-02-24, From 2021-01-01 |
| 2020-12-31 | -$15.54M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $57.02M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$86.97M | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | -$38.91M | n/m | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $93.73M | +278.9% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $24.74M | n/m | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | -$22.13M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$5.59M | n/m | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | -$11.09M | n/a | 2015-02-23, From 2012-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Xencor Inc (XNCR) | 2025-12-31 | -$138.27M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | -$13.62M | n/m |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | -$180.0K | n/m |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$162.73M | n/m |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | -$75.37M | n/m |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $238.50M | n/m |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | -$2.43M | n/m |
| Zymeworks Inc. (ZYME) | 2025-12-31 | -$34.53M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $22.82M | +291.4% |
Compare XNCR, LFCR, GYRE, URGN side by side · Screen every company in Pharmaceutical Preparations ↗